Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGMO's Cash to Debt is ranked higher than
98% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. SGMO: No Debt )
SGMO' s 10-Year Cash to Debt Range
Min: 1.71   Max: No Debt
Current: No Debt

Equity to Asset 0.85
SGMO's Equity to Asset is ranked higher than
87% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGMO: 0.85 )
SGMO' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.99
Current: 0.85

0.39
0.99
Interest Coverage No Debt
SGMO's Interest Coverage is ranked higher than
82% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGMO: No Debt )
SGMO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 17.71
M-Score: -1.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -80.68
SGMO's Operating margin (%) is ranked higher than
75% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. SGMO: -80.68 )
SGMO' s 10-Year Operating margin (%) Range
Min: -1114.07   Max: -50.32
Current: -80.68

-1114.07
-50.32
Net-margin (%) -80.03
SGMO's Net-margin (%) is ranked higher than
75% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. SGMO: -80.03 )
SGMO' s 10-Year Net-margin (%) Range
Min: -1050.8   Max: -48.73
Current: -80.03

-1050.8
-48.73
ROE (%) -16.99
SGMO's ROE (%) is ranked higher than
80% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. SGMO: -16.99 )
SGMO' s 10-Year ROE (%) Range
Min: -67.23   Max: -21.1
Current: -16.99

-67.23
-21.1
ROA (%) -14.61
SGMO's ROA (%) is ranked higher than
80% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. SGMO: -14.61 )
SGMO' s 10-Year ROA (%) Range
Min: -60.12   Max: -20.37
Current: -14.61

-60.12
-20.37
ROC (Joel Greenblatt) (%) -2032.94
SGMO's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. SGMO: -2032.94 )
SGMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3614.47   Max: -703.47
Current: -2032.94

-3614.47
-703.47
Revenue Growth (3Y)(%) -2.20
SGMO's Revenue Growth (3Y)(%) is ranked higher than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. SGMO: -2.20 )
SGMO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -38   Max: 68.7
Current: -2.2

-38
68.7
EBITDA Growth (3Y)(%) -4.50
SGMO's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. SGMO: -4.50 )
SGMO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -23.7   Max: 106.7
Current: -4.5

-23.7
106.7
EPS Growth (3Y)(%) -4.40
SGMO's EPS Growth (3Y)(%) is ranked higher than
69% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. SGMO: -4.40 )
SGMO' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.2   Max: 184.4
Current: -4.4

-25.2
184.4
» SGMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SGMO Guru Trades in Q1 2014

Jean-Marie Eveillard 400,000 sh (-52.81%)
Steven Cohen 509,662 sh (-54.55%)
» More
Q2 2014

SGMO Guru Trades in Q2 2014

Jean-Marie Eveillard 536,380 sh (+34.1%)
Steven Cohen 788,900 sh (unchged)
Jean-Marie Eveillard 2,500 sh (unchged)
» More
Q3 2014

SGMO Guru Trades in Q3 2014

Jean-Marie Eveillard 4,000 sh (unchged)
Steven Cohen 488,400 sh (unchged)
Jean-Marie Eveillard 536,380 sh (unchged)
Steven Cohen 641,500 sh (-18.68%)
» More
Q4 2014

SGMO Guru Trades in Q4 2014

Paul Tudor Jones 17,511 sh (New)
Joel Greenblatt 17,441 sh (New)
Jean-Marie Eveillard 559,780 sh (+4.36%)
Jean-Marie Eveillard 4,017 sh (unchged)
Steven Cohen 158,000 sh (-75.37%)
» More
» Details

Insider Trades

Latest Guru Trades with SGMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 New Buy$9.85 - $16.53 $ 17.0841%17441
Jean-Marie Eveillard 2014-06-30 Add 34.1%0.01%$11.71 - $17.95 $ 17.0819%536380
Jean-Marie Eveillard 2014-03-31 Reduce -52.81%0.02%$13.25 - $23.86 $ 17.08-11%400000
Jean-Marie Eveillard 2013-09-30 Add 99.73%0.01%$7.92 - $11.28 $ 17.0872%847550
Jean-Marie Eveillard 2013-06-30 Add 41.45%$7.31 - $10.65 $ 17.0896%424350
Jean-Marie Eveillard 2013-03-31 New Buy0.01%$6.01 - $10.8 $ 17.0892%300000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 0.34
SGMO's Forward P/E is ranked higher than
100% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SGMO: 0.34 )
N/A
P/B 5.60
SGMO's P/B is ranked higher than
75% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. SGMO: 5.60 )
SGMO' s 10-Year P/B Range
Min: 1.48   Max: 11.1
Current: 5.6

1.48
11.1
P/S 30.10
SGMO's P/S is ranked higher than
75% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. SGMO: 30.10 )
SGMO' s 10-Year P/S Range
Min: 4.84   Max: 129.75
Current: 30.1

4.84
129.75
EV-to-EBIT -23.63
SGMO's EV-to-EBIT is ranked lower than
52% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SGMO: -23.63 )
SGMO' s 10-Year EV-to-EBIT Range
Min: -45.3   Max: -0.9
Current: -23.63

-45.3
-0.9
Current Ratio 8.88
SGMO's Current Ratio is ranked higher than
86% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. SGMO: 8.88 )
SGMO' s 10-Year Current Ratio Range
Min: 5.06   Max: 55.31
Current: 8.88

5.06
55.31
Quick Ratio 8.88
SGMO's Quick Ratio is ranked higher than
86% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. SGMO: 8.88 )
SGMO' s 10-Year Quick Ratio Range
Min: 5.06   Max: 55.31
Current: 8.88

5.06
55.31
Days Sales Outstanding 81.85
SGMO's Days Sales Outstanding is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. SGMO: 81.85 )
SGMO' s 10-Year Days Sales Outstanding Range
Min: 1.14   Max: 284.62
Current: 81.85

1.14
284.62

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.33
SGMO's Price/Net Cash is ranked higher than
86% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. SGMO: 9.33 )
SGMO' s 10-Year Price/Net Cash Range
Min: 0.96   Max: 17.78
Current: 9.33

0.96
17.78
Price/Net Current Asset Value 8.85
SGMO's Price/Net Current Asset Value is ranked higher than
85% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. SGMO: 8.85 )
SGMO' s 10-Year Price/Net Current Asset Value Range
Min: 0.95   Max: 17.61
Current: 8.85

0.95
17.61
Price/Tangible Book 5.66
SGMO's Price/Tangible Book is ranked higher than
80% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. SGMO: 5.66 )
SGMO' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 12.58
Current: 5.66

0.89
12.58
Price/DCF (Projected) 33.49
SGMO's Price/DCF (Projected) is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SGMO: 33.49 )
SGMO' s 10-Year Price/DCF (Projected) Range
Min: 21.15   Max: 28.25
Current: 33.49

21.15
28.25
Price/Median PS Value 1.25
SGMO's Price/Median PS Value is ranked higher than
86% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. SGMO: 1.25 )
SGMO' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 7.35
Current: 1.25

0.24
7.35
Earnings Yield (Greenblatt) -4.20
SGMO's Earnings Yield (Greenblatt) is ranked higher than
80% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SGMO: -4.20 )
SGMO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.2   Max: 0
Current: -4.2

-4.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBY.Germany,
Sangamo BioSciences Inc was incorporated in June 1995 in the state of Delaware. It is a clinical stage biopharmaceutical that company engaged in the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. The Company is engaged in the development of novel human therapeutics and is building a pipeline of ZFP Therapeutics. Its ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of its ZFN technology and is being evaluated in an ongoing Phase 2 and two Phase 1/2 clinical trials. It has preclinical ZFP Therapeutic development programs in hemophilia and Parkinsons disease. In addition, it has research stage programs in other monogenic diseases; genetic conditions that result from a defect in a single gene, including hemoglobinopathies such as sickle cell anemia, lysosomal storage diseases and certain immunodeficiencies. On 8 January 2014, the Company has a collaborative partnership with Biogen Idec Inc.to research, develop and commercialize our preclinical ZFP Therapeutic development program, in hemoglobinopathies, and targeting sickle cell disease (SCD) and beta-thalassemia. It has a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon its ZFP technology as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr and is selling transgenic animals through its SAGETM Labs business unit. The Company has a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, it has provided DAS with access to its ZFP technology and the exclusive rights to use it to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. DAS markets its ZFN technology under the trademark EXZACTTM Precision Technology. The Company has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic, or prophylactic purposes. It faces competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies; for establishing relationships with academic and research institutions; and for licenses to proprietary technology. Its therapeutic or pharmaceutical products undergoes rigorous preclinical testing and clinical trials in humans and an extensive regulatory clearance process implemented by the U.S. Food and Drug Administration (FDA) under the federal Food, Drug and Cosmetic Act.
» More Articles for SGMO

Headlines

Articles On GuruFocus.com
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 03 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2009 
Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results Feb 04 2009 


More From Other Websites
Study of potential HIV 'cure' wins FDA nod Mar 03 2015
Sangamo Biosciences (SGMO) is in Overbought Territory: What's Next? - Tale of the Tape Mar 03 2015
Sangamo BioSciences Presents New Clinical Data at CROI 2015 From Trial of ZFP Therapeutic® Designed... Feb 26 2015
Sangamo BioSciences Presents New Clinical Data at CROI 2015 From Trial of ZFP Therapeutic® Designed... Feb 26 2015
Sangamo BioSciences Announces Presentation At The Cowen And Company 35th Annual Health Care... Feb 25 2015
SANGAMO BIOSCIENCES INC Files SEC form 10-K, Annual Report Feb 25 2015
Sangamo BioSciences Announces Presentation At The Cowen And Company 35th Annual Health Care... Feb 25 2015
Sangamo BioSciences Presents Data At 11th Annual WorldSymposium™ Meeting Supporting In Vivo... Feb 12 2015
Sangamo reports 4Q loss Feb 10 2015
Sangamo reports 4Q loss Feb 10 2015
Sangamo BioSciences Inc Earnings Call scheduled for 5:00 pm ET today Feb 10 2015
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 10 2015
Sangamo BioSciences Reports Fourth Quarter and Full Year 2014 Financial Results Feb 10 2015
Q4 2014 Sangamo BioSciences Inc Earnings Release - After Market Close Feb 10 2015
Will Sangamo (SGMO) Disappoint This Earnings Season? - Analyst Blog Feb 09 2015
Sangamo BioSciences Announces Presentation At The 2015 Leerink Global Healthcare Conference Feb 05 2015
Sangamo BioSciences Announces Presentation At The 2015 Leerink Global Healthcare Conference Feb 05 2015
Sangamo BioSciences Announces FDA Acceptance of IND to Initiate Clinical Trial of its Novel ZFP... Feb 04 2015
Sangamo BioSciences Announces Fourth Quarter and Full Year 2014 Conference Call and Webcast Feb 03 2015
Sangamo BioSciences To Highlight 2015 Catalysts And Advancement Of ZFP Therapeutic Programs At The... Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK